Nurix Therapeutics, Inc. - COMMON STOCK (NRIX)
CUSIP: 67080M103
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 102,616,132
- Total 13F shares
- 64,996,165
- Share change
- +15,882,360
- Total reported value
- $1,356,466,249
- Put/Call ratio
- 259%
- Price per share
- $20.87
- Number of holders
- 172
- Value change
- +$340,051,233
- Number of buys
- 110
- Number of sells
- 63
Quarterly Holders Quick Answers
What is CUSIP 67080M103?
CUSIP 67080M103 identifies NRIX - Nurix Therapeutics, Inc. - COMMON STOCK in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 67080M103:
Top shareholders of NRIX - Nurix Therapeutics, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock Finance, Inc. |
13F
|
Company |
4.5%
|
4,580,414
|
$67,332,086 | — | 31 Mar 2024 | |
| Redmile Group, LLC |
13F
|
Company |
4.4%
|
4,483,016
|
$65,900,335 | — | 31 Mar 2024 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
3.8%
|
3,882,125
|
$57,067,238 | — | 31 Mar 2024 | |
| Deep Track Capital, LP |
13F
|
Company |
2.9%
|
2,997,830
|
$44,068,101 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.7%
|
2,729,336
|
$40,121,239 | — | 31 Mar 2024 | |
| ARK Investment Management LLC |
13F
|
Company |
2.6%
|
2,635,338
|
$38,739,473 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.5%
|
2,584,300
|
$37,989,210 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
2.5%
|
2,530,799
|
$37,202,747 | — | 31 Mar 2024 | |
| Third Rock Ventures III, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
3,509,348
|
$35,104,359 | — | 06 May 2021 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.1%
|
2,196,169
|
$32,284,000 | — | 31 Mar 2024 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
1.5%
|
1,499,368
|
$22,040,710 | — | 31 Mar 2024 | |
| WASATCH ADVISORS LP |
13F
|
Company |
1.2%
|
1,236,753
|
$18,180,269 | — | 31 Mar 2024 | |
| Bain Capital Life Sciences Investors, LLC |
13F
|
Company |
1.1%
|
1,132,397
|
$16,646,236 | — | 31 Mar 2024 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
1.1%
|
1,115,000
|
$16,390,500 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.1%
|
1,100,335
|
$16,177,014 | — | 31 Mar 2024 | |
| COLUMN GROUP L P |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
1,442,739
|
$14,431,862 | — | 07 May 2021 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.94%
|
966,453
|
$14,206,859 | — | 31 Mar 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
0.87%
|
892,110
|
$13,114,017 | — | 31 Mar 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.79%
|
810,253
|
$11,910,719 | — | 31 Mar 2024 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.71%
|
726,941
|
$10,686,033 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.63%
|
642,190
|
$9,440,193 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.48%
|
492,666
|
$7,242,191 | — | 31 Mar 2024 | |
| JACOBS LEVY EQUITY MANAGEMENT, INC |
13F
|
Company |
0.42%
|
434,413
|
$6,385,871 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.41%
|
418,823
|
$6,156,699 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.39%
|
404,010
|
$5,938,947 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.36%
|
374,249
|
$5,501,460 | — | 31 Mar 2024 | |
| BESSEMER GROUP INC |
13F
|
Company |
0.35%
|
357,287
|
$5,252,000 | — | 31 Mar 2024 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
0.31%
|
314,762
|
$4,627,001 | — | 31 Mar 2024 | |
| Invesco Ltd. |
13F
|
Company |
0.3%
|
312,910
|
$4,599,777 | — | 31 Mar 2024 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.29%
|
300,000
|
$4,410,000 | — | 31 Mar 2024 | |
| WestHill Financial Advisors, Inc. |
13F
|
Company |
0.28%
|
283,333
|
$4,164,995 | — | 31 Mar 2024 | |
| PRIMECAP MANAGEMENT CO/CA/ |
13F
|
Company |
0.27%
|
279,000
|
$4,101,300 | — | 31 Mar 2024 | |
| Opaleye Management Inc. |
13F
|
Company |
0.26%
|
267,210
|
$3,927,987 | — | 31 Mar 2024 | |
| Schonfeld Strategic Advisors LLC |
13F
|
Company |
0.26%
|
262,162
|
$3,853,781 | — | 31 Mar 2024 | |
| Parkman Healthcare Partners LLC |
13F
|
Company |
0.24%
|
250,000
|
$3,675,000 | — | 31 Mar 2024 | |
| Connor, Clark & Lunn Investment Management Ltd. |
13F
|
Company |
0.23%
|
237,104
|
$3,485,429 | — | 31 Mar 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
0.23%
|
233,136
|
$3,427,099 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.21%
|
214,716
|
$3,156,325 | — | 31 Mar 2024 | |
| Trexquant Investment LP |
13F
|
Company |
0.21%
|
212,879
|
$3,129,321 | — | 31 Mar 2024 | |
| Rafferty Asset Management, LLC |
13F
|
Company |
0.21%
|
211,425
|
$3,107,948 | — | 31 Mar 2024 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.21%
|
211,316
|
$3,106,345 | — | 31 Mar 2024 | |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP |
13F
|
Company |
0.18%
|
187,743
|
$2,760,000 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0.18%
|
184,780
|
$2,716,266 | — | 31 Mar 2024 | |
| NORGES BANK |
13F
|
Company |
0.18%
|
180,800
|
$2,657,760 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.17%
|
179,300
|
$2,636,000 | — | 31 Mar 2024 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.17%
|
177,900
|
$2,615,130 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.16%
|
168,942
|
$2,483,447 | — | 31 Mar 2024 | |
| ExodusPoint Capital Management, LP |
13F
|
Company |
0.16%
|
165,603
|
$2,434,000 | — | 31 Mar 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.16%
|
160,293
|
$2,355,000 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.16%
|
159,218
|
$2,340,505 | — | 31 Mar 2024 |
Institutional Holders of Nurix Therapeutics, Inc. - COMMON STOCK (NRIX) as of Q2 2024
As of 30 Jun 2024,
Nurix Therapeutics, Inc. - COMMON STOCK (NRIX) was held by
172 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
64,996,165 shares.
The largest 10 holders included
BlackRock Inc., Redmile Group, LLC, Deep Track Capital, LP, BAKER BROS. ADVISORS LP, VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, ARK Investment Management LLC, and T. Rowe Price Investment Management, Inc..
This page lists
172
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
138
Q2 2024 holders
172
Holder diff
34
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.